SynthesisFrontiers in medicine2024

Efficacy and safety of PD-1/PD-L1 inhibitor-based immune combination therapy versus sorafenib in the treatment of advanced hepatocellular carcinoma: a meta-analysis.

Mingjin She et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.